Companies - Pharming

Price

 
Price
€ 0,80
Change
€ 0,01
Change %
1,11%
Open
€ 0,79
High
€ 0,80
Low
€ 0,78
Volume
2.787.944

Profile

 
Profile
Pharming is an innovative biotechnology company that has the mission to create value for all shareholders through the development of therapeutic products for humans. Pharming's goal is the development and commercialization of therapeutic proteins for difficult to treat or non-treatable diseases, thus helping patients and add value for shareholders. The developed applications can be applied in the case of genetic anomalies or use in resolving tissue damage after surgery. The current focus of Pharming is on product innovation. Future growth of the company is pursued through licensing products, its technology and strategic transactions.
Industry
Biotechnology
Description
Companies in the biotechnology industry are performing research and development activities for the purpose of discovering new drugs and diagnostics. The turnover of these companies comes from sales of these products or the sale of licenses of drugs and diagnostic to other companies.

Key figures (2020)

 
The ratios below are calculated using the last known share price and the last known company financials.

Ratios per share

Price to Earnings
15,383
Price to Earnings (3 years)
16,181
Price to Earnings (5 years)
-777,144
Price to earnings growth
-
Price/cashflow
15,383
Price/net cashflow
6,657
Price/book value
3,402
Price to sales
2,714

Ratios for dividend

Dividend yield
-
Pay out
-

Valuation ratios

Market value/PE
3,402
Market value/turnover
2,714
Enterprise value/turnover
1,903

Return ratios

Return on private equity
22,12%
Return on total equity
9,70%
Profit margin
17,64%

Risk ratios

Solvability
0,438
Solvability
1,781
Current ratio
3,425
Debt to Equity
1,281

Value invest ratios

Grahams Number
€ 0,04
Grahams Value
€ -0,76
Grahams Product
52,339
Grahams Product (3 years)
55,055

2020

 

Profit and loss

Net profit (x 1 mln)
€ 33,04
Turnover (x 1 mln)
€ 187,29
Cashflow(x 1 mln)
€ 33,04
Net cashflow(x 1 mln)
€ 76,35

Balance

Private equity (x 1 mln)
€ 149,38
Foreign equity (x 1 mln)
€ 191,38
Current assets (x 1 mln)
€ 214,34
Current liabilities (x 1 mln)
€ 62,58
Working capital (x 1 mln)
€ 151,76
Balance total (x 1 mln)
€ 340,76

Share

Outstanding shares (x 1 mln)
636,270
Price year-end
€ 1,27
Dividend per share
-
Earnings per share
€ 0,05
Cashflow per share
€ 0,05
Net cashflow per share
€ 0,12
Book value per share
€ 0,23
Stockmarket value (x 1 mln)
€ 809,34

History

 
Year
2020
2019
2018
2017
2016
Net profit (x 1 mln)
€ 33,04
€ 36,20
€ 24,99
€ -79,96
€ -17,54
Turnover (x 1 mln)
€ 187,29
€ 169,02
€ 135,13
€ 89,62
€ 16,21
Price year-end
€ 1,27
€ 1,57
€ 0,76
€ 1,13
€ 0,22
Year high
€ 1,60
€ 1,64
€ 1,62
€ 1,38
€ 0,32
Year low
€ 0,75
€ 0,71
€ 0,64
€ 0,22
€ 0,15
Outstanding shares (x 1 mln)
636,270
631,320
621,500
579,010
407,687
Price to Earnings
24,496
27,337
18,839
-8,197
-5,044
Earnings per share
€ 0,05
€ 0,06
€ 0,04
€ -0,14
€ -0,04
Dividends
-
-
-
-
-
Dividend yield
-
-
-
-
-
Pay out
-
-
-
-
-
Private equity (x 1 mln)
€ 149,38
€ 104,68
€ 61,75
€ 18,80
€ 27,47
PE per share
€ 0,23
€ 0,17
€ 0,10
€ 0,03
€ 0,07
Balance total (x 1 mln)
€ 340,76
€ 228,21
€ 214,57
€ 166,19
€ 126,78
Stockmarket value (x 1 mln)
€ 809,34
€ 989,59
€ 470,79
€ 655,44
€ 88,47

Company analysis

 

Analysis of profit indicators

Average profit per share (10 years)
€ -0,10
Standard deviation average profit
€ 0,14 (-142,98%)
Average annual growth rate
-8,48%
Compound annual growth percentage
8,57%

© 2009 - 2021 Skuzet. All Rights Reserved.

We use cookies on our website. Some of them are essential for the operation of the site, while others help us to improve this site and the user experience (tracking cookies). You can decide for yourself whether you want to allow cookies or not. Please note that if you reject them, you may not be able to use all the functionalities of the site.